The Price of Invisibility: A HIV Disaster Cascades Through Latino America

WASHINGTON, DC – June 25, 2026 – For years, the narrative surrounding the U.S. HIV epidemic has been one of steady, hard-won progress. National data shows a commendable 19% decline in new infections from 2010 to 2022. But beneath this encouraging surface, a parallel and deeply alarming trend has been accelerating. Over that same period, new HIV infections among Latinos surged by 12%. In 2023, they jumped another 8% in a single year—the steepest rise of any demographic group.

This isn't a statistical anomaly; it is what researchers from the Johns Hopkins University School of Nursing are calling a "cascading disaster." In a stark new paper, "The Price of Invisibility," published in the journal AIDS, they argue that a decade of structural neglect, policy failures, and eroding public health infrastructure has created a crisis that threatens to undermine the nation's entire strategy for ending the HIV epidemic.

"What we are documenting is not a temporary setback," warns Dr. Vincent Guilamo-Ramos, the paper's lead author and Director of the Center for Latino Adolescent and Family Health (CLAFH) at Johns Hopkins. "It is a cascading disaster driven by compounding failures in policy, access, representation, and accountability." His message, delivered just ahead of the 26th International AIDS Conference, is a direct challenge to the U.S. public health establishment: progress that leaves a major community behind is not progress at all.

A System of Compounding Failures

The report meticulously deconstructs how this crisis developed. The most dramatic figures are found among Latino men who have sex with men (MSM). While infections among MSM nationwide fell 15% between 2010 and 2022, they grew 24% for Latino MSM. For those aged 25 to 34, the increase was a staggering 95%. By 2022, Latino MSM accounted for the single highest number of new HIV infections of any group in the country, a grim milestone that highlights a catastrophic breakdown in targeted prevention.

This breakdown is multifaceted. Access to Pre-Exposure Prophylaxis (PrEP), a cornerstone of modern HIV prevention, has never reached parity for Latinos, and the modest gains made before the COVID-19 pandemic have been all but erased. The problem is not merely historical; it extends to the cutting edge of pharmaceutical innovation. The paper points to a major pharmacy benefits manager refusing to reimburse lenacapavir, a newly approved long-acting PrEP injectable, at its annual cost of over $28,000. For a population with significant numbers of uninsured or underinsured individuals, such gatekeeping effectively places a breakthrough prevention tool out of reach, perpetuating the cycle of inequity.

Beyond prevention, the treatment cascade—the series of steps from diagnosis to viral suppression—is riddled with gaps. In 2023, more than a quarter of Latinos with diagnosed HIV received no care at all, and over a third had not achieved a suppressed viral load, a critical metric for both individual health and preventing further transmission. These are not just numbers; they represent systemic barriers, from a lack of culturally and linguistically competent healthcare to medical mistrust born from discrimination.

The High Cost of Policy Retreat

This cascading disaster is not happening in a vacuum. It is being actively fueled by policy decisions and funding threats at both the state and federal levels. The paper sounds the alarm on proposed Medicaid cuts, which would endanger the nearly two-thirds of Latinos with HIV who depend on public insurance or the Ryan White HIV/AIDS Program—the nation’s crucial safety net for HIV care.

The impact is already being felt. In Florida, which accounts for over 10% of all new Latino HIV diagnoses, a recent tightening of eligibility for the AIDS Drug Assistance Program (ADAP) puts an estimated 16,000 people at risk of losing access to their life-saving antiretroviral therapy. Similar threats loom elsewhere. Proposed federal cuts threaten $600 million in funding for HIV and STI programming in key states like California, Illinois, Colorado, and Minnesota, which collectively represent more than a quarter of new Latino diagnoses. This retreat from investment dismantles the very infrastructure needed to fight the epidemic.

Compounding these policy failures is a weakening of the data infrastructure itself. The authors note that delays in federal HIV surveillance reporting, attributed to workforce reductions, mean the most current incidence estimates are unavailable. This creates a dangerous feedback loop. As Dr. Guilamo-Ramos states, "Invisibility has a price. When data are delayed, when Latino communities are deprioritized... preventable infections continue and opportunities for national progress are lost." Without timely, granular data, public health officials are flying blind, unable to target resources effectively or hold systems accountable for their failures.

A Call for Visibility and Action

The Johns Hopkins paper is more than a diagnosis; it is a clear-eyed call to action. The authors outline a series of concrete steps for reversing the crisis, all centered on a core principle: making the Latino community visible in the national HIV response. This includes protecting funding for surveillance and prevention, preserving Medicaid and the Ryan White Program, and expanding culturally tailored services.

Crucially, they call for ensuring reimbursement for new innovations like long-acting PrEP and increasing Latino representation across the health workforce and in public health leadership. The argument is clear: policy and care cannot be effective if they are not shaped by the realities of the communities they are meant to serve.

For the broader U.S. strategy, these findings represent a critical inflection point. The goal of ending the HIV epidemic is a complex endeavor, reliant on a value chain that includes pharmaceutical innovation, robust public funding, equitable insurance access, and trusted community-level care. The escalating crisis in the Latino community demonstrates that a weakness in any part of that chain, particularly when driven by systemic neglect, can have devastating consequences that ripple across the entire effort. As Dr. Guilamo-Ramos concludes, "Ending HIV is not a zero-sum proposition: closing the widening gaps in Latino communities will accelerate progress for everyone, while inaction jeopardizes national progress."